Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Amanda Anderson

PhD, BSc (Hons)

Divisional Safety Officer and Facilities Manager for NDCLS

I am a Postdoctoral researcher with a strong background in antibody development and use. 

I have previously worked on the preclinical development of therapeutic antibodies for a variety of cancer indications, but I am currently investigating the role of the FOXP family of transcription factors in haematological malignancies, in particular diffuse large B-cell lymphoma (DLBCL), with a view to improving treatment options for patients. DLBCL is the most common type of B-cell lymphoma and outcomes for patients who fail to respond to current treatment options is poor. 

A number of subtypes of DLBCL have been identified including a poor prognosis type with an activated B-cell (ABC)-like gene expression signature. 

I am using CRISPR/Cas9 technology to identify regulators of FOXP1 expression in this aggressive subtype to identify novel targets for therapy. My work uses a wide range of techniques across the disciplines of molecular biology, biochemistry and cell biology, but I have a particular expertise in antibody production and validation, and in histological and immunohistochemical methods.

Outside of my research, I am also the Deputy Divisional Safety Officer for NDCLS.